The online version of this article (doi:10.1186/s12890-015-0123-y) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
MP performed all assays. MP, JCD, MRG, CG and NSB participated in clinical data reviewing. MP, MB and EP designed the real-time PCR. MD conceived the study. MP and MD participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final version of the manuscript.
Michael Phelippeau is a pulmonologist and resident in infectious diseases medicine with particular interest in tuberculosis and respiratory mycobacterial diseases.
Mycobacterium lentiflavum is rarely isolated in respiratory tract samples from cystic fibrosis patients. We herein describe an unusually high prevalence of M. lentiflavum in such patients.
M. lentiflavum, isolated from the respiratory tract of cystic fibrosis patients, was identified using both rpoB partial sequencing and detected directly in the sputum by using real-time PCR targeting the smpB gene.
M. lentiflavum emerged as the third most prevalent nontuberculous mycobacterial species isolated in cystic fibrosis patients in Marseille, France. Six such patients were all male, and two of them may have fulfilled the American Thoracic Society clinical and microbiological criteria for M. lentiflavum potential lung infection.
M. lentiflavum was the third most common mycobacteria isolated in cystic fibrosis patients, particularly in six male patients. M. lentiflavum outbreaks are emerging particularly in cystic fibrosis patients.
Additional file 1: Table S1. Mycobacterium species tested for the specificity/sensitivity assay of real-time PCR for M. lentiflavum species. (PDF 43 kb)12890_2015_123_MOESM1_ESM.pdf
Additional file 2: Figure S1. Clinical and microbiological data concerning two cystic fibrosis patients who yielded more than one M. lentiflavum isolate and who may fulfill the American Thoracic Society’s clinical and microbiological criteria for NTM lung infection. BMI: Body Mass Index. (PDF 121 kb)12890_2015_123_MOESM2_ESM.pdf
Asiimwe B, Bagyenzi GB, Ssengooba W, Mumbowa F, Mboowa G, Wajja A, et al. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda. BMC Infect D. 2013;13:88–94. CrossRef
Seddon P, Fidler K, Raman S, Wyatt H, Ruiz G, Elston C, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom. Emerg Infect D. 2009;19:1128–30. CrossRef
Miller K, Harrington SM, Procop GW. Acid-fast smear and histopathology results provide guidance for the appropriate use of broad-range polymerase chain reaction and sequencing for mycobacteria. Arch Pathol Lab Med. 2015. [Epub ahead of print].
Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2014;121:3554–63. CrossRef
- Prevalence of Mycobacterium lentiflavum in cystic fibrosis patients, France
Nathalie Stremler le Bel
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II